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Background: Gout is a common arthritic disease resulting from elevated serum uric acid (SUA) level. A large
meta-analysis including 28,141 individuals identified nine single nucleotide polymorphisms (SNPs) associated with
altered SUA level in a Caucasian population. However, raised SUA level alone is not sufficient for the development
of gout arthritis and most of these SNPs have not been studied in a Han Chinese population. Here, we performed
a case–control association analysis to investigate the relationship between these SUA correlated SNPs and gout
arthritis in Han Chinese.
Methods: A total of 622 ascertained gout p9atients and 917 healthy controls were genotyped. Genome-wide
significant SNPs, rs12129861, rs780094, rs734553, rs742132, rs1183201, rs12356193, rs17300741 and rs505802 in the
previous SUA study, were selected for our analysis.
Results: No deviation from the Hardy–Weinberg equilibrium was observed either in the case or control cohorts
(corrected p > 0.05). Three SNPs, rs780094 (located in GCKR, corrected p = 1.78E−4, OR = 0.723), rs1183201 (located
in SLC17A1, corrected p = 1.39E−7, OR = 0.572) and rs505802 (located in SLC22A12, corrected p = 0.007, OR = 0.747),
were significantly associated with gout on allelic level independent of potential cofounding traits. While the
remaining SNPs were not replicated. We also found significant associations of uric acid concentrations with these
three SNPs (rs780094 in GCKR, corrected p = 3.94E−5; rs1183201 in SLC17A1, corrected p = 0.005; rs505802 in
SLC22A12, corrected p = 0.003) and of triglycerides with rs780094 (located in GCKR, corrected p = 2.96E−4).
Unfortunately, SNP-SNP interactions for these three significant SNPs were not detected (rs780094 vs rs1183201,
p = 0.402; rs780094 vs rs505802, p = 0.434; rs1183201 vs rs505802, p = 0.143).
Conclusions: Three SUA correlated SNPs in Caucasian population, rs780094 in GCKR, rs1183201 in SLC17A1 and
rs505802 in SLC22A12 were confirmed to be associated with gout arthritis and uric acid concentrations in Han
Chinese males. Considering genetic differences among populations and complicated pathogenesis of gout
arthritis, more validating tests in independent populations and relevant functional experiments are suggested
in future.
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Gout is the most common cause of arthritis and elevated
serum uric acid (SUA) level, namely hyperuricemia, is an
important independent risk factor for gout [1]. There
are extensive data which suggests that the incidence
and prevalence of hyperuricemia and gout increased
markedly over the past decades worldwide [2–5]. In
addition, hyperuricemia and gout have been independ-
ently linked to other endocrine and metabolic diseases
including obesity, insulin resistance, diabetes, dyslipid-
emia and cardiovascular diseases like hypertension and
coronary heart disease [1]. Gout is a lifelong disease
inflicting a considerable burden of illness upon employers
in terms of treatment costs as well as other work-related
“benefits” [6].
In addition to known environmental factors such as
high-purine diet, drinking and smoking [1], genetic
components are also involved in the occurrence of hy-
peruricemia and gout, with heritability up to 40 % [7].
Identifying genetic factors is necessary to improve the
etiological diagnosis and management of hyperurice-
mia and gout. With the rapid development of genetic
methods, especially genome-wide association studies
(GWAS), dozens of variants of genes that are associ-
ated with SUA levels or/and gout are found now. And
most of these genes are involved with the renal uric
acid-transport system rather than inflammatory path-
ways. Among these, the most significant findings are
variants located within ABCG2 (ATP-binding cassette,
sub-family G, member 2), SLC2A9 (solute carrier fam-
ily 2 member 9) and SLC22A12 (solute carrier family
22 member 12), having been consistently replicated
across different ethnic groups including Europeans,
Chinese, Japanese, Koreans and Mexican Americans
[8–16]. Kolz et al. performed a large meta-analysis in-
cluding 28,141 individuals and identified nine different
loci associated with SUA levels. These included the
previously reported genes SLC22A12, SLC2A9, ABCG2,
SLC17A1-SLC17A3 and the newly identified genes PDZK1,
GCKR, LRRC16A, SLC16A9 and SLC22A11 [17]. Another
large-scale GWAS from >140,000 individuals of European
ancestry for SUA level also replicated most of these nine
significant loci and additional 18 new loci [18]. A study of
Netherland residents corroborated the association of
PDZK1, GCKR, SLC16A9 and SLC22A11 loci with altered
SUA concentrations, but failed to replicate the LRRC16A
locus as a risk factor [19]. A study of Germans investi-
gated the association of all the above SNPs with gout and
only identified rs734553 in SLC2A9 and rs2231142 in
ABCG2 to be risk factors [20]. The “A” allele of rs742132
in the LRRC16A gene was found to be risk allele for gout
in two independent association studies both from Japanese
origin [21, 22]. The “A” allele of rs780094 in GCKR
gene has been validated to be risk allele for goutconsistently in Chinese, Japanese and New Zealand
European and Polynesian case–control sample sets
[22–24]. SNP rs1183201 in SLC17A1 was also corrob-
orated to be associated with gout in New Zealand
Caucasians [24, 25] and rs1165205 in SLC17A3 (in high
linkage disequilibrium (LD) with rs1183201 in HapMap-
CEU, r2 = 0.889) was replicated in European whites [8]. No-
ticeably, a recent GWAS in Chinese population identified
two previously reported SUA loci of SLC2A9 (rs11722228)
and ABCG2 (rs2231142, rs4148152 and rs3114018,
rs4148155), but failed to replicate the remaining loci
which were associated with SUA level in Europeans
[11]. Other replication studies from Han Chinese ori-
gin also reported additional associations for variants
in these loci with gout disease, especially for SLC2A9
[25–27], ABCG2 [28–31]and SLC22A12 [32–34]. LD
structure between these variants may differ among dif-
ferent ethnics. Both rs16890979 and rs6855911 were
in strong LD with rs734553 in HapMap-CEU (r2 =
0.957 and 1.0, respectively) and were confirmed to be
associated with gout in Europeans [8, 20]. In Chinese
population, rs6855911 (in strong LD with rs734553 in
HapMap-CHB, r2 = 1.0) was not identified in gout-
control groups but was replicated in high-uric-acid
and normal-uric-acid groups [26] and rs16890979 was
in much lower LD with rs734553 from HapMap-CHB
(r2 = 0.494). GCKR rs780093 (in strong LD with
rs780094 in HapMap-CEU and HapMap-CHB, r2 =
1.0) was nominally associated with gout in Europeans
and Chinese [12, 23]. SLC17A1 rs1165196 (in strong
LD with rs1183201 from HapMap-CEU, r2 = 0.889)
was associated with SUA level in whites [8, 12]. However,
both rs1165196 and 1183201 (in strong LD with r2 =
0.904 in HapMap-CHB) showed no significant difference
between the case–control groups [35]. Besides, another
GWAS and meta-analysis both for SUA level in Japanese
population also corroborated the three well-known loci of
SLC2A9 (rs11722228 and rs3775948), ABCG2 (rs4148155
and rs2725220) and SLC22A12 (rs506338 and rs504915)
[13, 14]. Considering the inconsistency among these
association studies and different genetic structure in
different populations, a further validation study in dif-
ferent populations is necessary. Therefore, we performed
a genetic association study of these SUA loci (PDZK1,
GCKR, SLC2A9, LRRC16A, SLC17A1, SLC16A9, SLC22A11
and SLC22A12) in gout patients and normal control volun-
teers of Han Chinese origin. SNP rs2231142 in ABCG2
were excluded from this study since our group and other
domestic institutions have clearly clarified consistent
association between this site and gout [27–29, 31, 35].
Besides, we don’t assess the relationship of the 18 new
loci with gout in the present study considering that the pro-
portion of variance in SUA concentrations explained by
these new loci was as low as 1.8 % in total [18].
Table 1 Characteristics of gout patients and controls
Variable Cases (N = 622) Controls (N = 917) P value
Age (year) 51.95 ± 13.68 47.56 ± 12.70 <0.001
BMI (kg/m2) 27.23 ± 3.77 25.401 ± 3.10 <0.001
SBP (mmHg) 134.07 ± 17.06 132.31 ± 19.53 0.098
DBP (mmHg) 87.75 ± 12.19 84.15 ± 12.19 <0.001
Glu (mmol/L) 6.50 ± 1.76 5.87 ± 1.85 <0.001
Tri (mmol/L) 2.49 ± 2.25 1.53 ± 1.17 <0.001
Cho (mmol/L) 5.15 ± 1.13 5.31 ± 1.43 0.025
UN (mmol/L) 5.34 ± 2.50 5.39 ± 2.42 0.715
Cre (μmol/L) 88.00 ± 40.42 80.34 ± 17.54 <0.001
UA (μmol/L) 475.88 ± 123.04 297.97 ± 47.41 <0.001
Values denote means ± standard deviations; BMI, body mass index; SBP,
Systolic blood pressure; DBP, Diastolic blood pressure; Glu, Blood glucose; Tri,
Triglycerides; Cho, Cholesterol; UN, Urea nitrogen; Cre, Creatinine; UA, Uric acid
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Participants and Phenotypes
All the patients and controls were of Han Chinese origin
and had long-term residence in the coastal areas of
Shandong Province. A total of 622 unrelated cases were
recruited from the gout clinic at the Affiliated Hospital
of Qingdao University and were diagnosed with primary
gout by experienced physicians according to criteria
established by the American College of Rheumatology
[36]. All 917 unrelated controls who had SUA values
below 420 μmol/L, and never suffered from an acute at-
tack of gouty arthritis were recruited. All participants
with relevant medication including allopurinol and lipid-
lowering drugs etc., a family history of gout and severe
illness, such as hepatitis or cancer, were excluded.
Notably, only males were recruited in this study due to
less than 5 % of our outpatients were female, not
sufficient to conduct a statistical analysis. This study was
approved by the Ethics Committee of Affiliated Hospital
of Qingdao University. All participants gave their written
informed consent. The study was in accordance with the
principles of the current version of the Declaration of
Helsinki.
Phenotype details including age, height and weight
were collected in a questionnaire at the time of admis-
sion and body mass index (BMI) was calculated from
the calculation formula weight (kg)/height (m) 2. Systolic
blood pressure (mmHg) and diastolic blood pressure
(mmHg) were measured and recorded by physicians on
our gout clinic. Related biochemical indicators includ-
ing blood glucose, triglycerides, total cholesterol, urea
nitrogen, creatinine and uric acid in the plasma of all
the participants were measured using an automated
multichannel chemistry analyzer (Model 200; Toshiba,
Tokyo, Japan). The information of phenotype details
and biochemical indicators in the two cohorts is listed
in Table 1.
SNP Selection and Genetic Analyses
Eight SNPs (rs12129861 at Chr1, rs780094 at Chr2,
rs734553 at Chr4, rs742132 at Chr6, rs1183201 at Chr6,
rs12356193 at Chr10, rs17300741 at Chr11, rs505802 at
Chr11) were determined by a large-scale meta-analysis for
SUA values (shown in Table 2). SNP rs2231142 in ABCG2
were excluded from this study since our group and other
domestic institutions have clearly clarified consistent
association between this site and gout [27–29, 31, 35].
Genomic DNA was extracted from peripheral leukocytes
according to the manufacturer’s protocols (Lifefeng Bio-
tech Co., Ltd, Shanghai, China). Extracted DNA was
confirmed and quantified with a NanoDrop 1000
Spectrophotometer (Thermo Scientific, USA). For the
genotyping of these SNPs, PCR amplification was per-
formed using the Gene Amp PCR System 9600 (AppliedBiosystems, Foster City, CA, USA). 3 % agarose gel
electrophoresis was performed to separate the PCR
products. Finally, DNA genotyping was performed
using PRISM 3730 instruments (Applied Biosystems,
Foster City, CA, USA). The primer sequences (included as
additional files) were designed using Primer 3 online
Version 0.4.0 and obtained from Hanyu Biotech Co., Ltd,
Shanghai, China.
Statistical Analyses
Clinical data between case–control cohorts was com-
pared using a t test by SPSS 19.0. Before the association
analysis was performed, Hardy-Weinberg equilibrium
(HWE) for the case and control group respectively was
evaluated to determine whether these genotype distribu-
tions achieved genetic equilibrium (threshold set to
0.05). In the case–control study, the differences in allele
frequencies were compared using chi-square test with
odds ratios (ORs) and their 95 % confidence intervals
(CI) reported. Logistic regression which considered each
of the potential confounding covariates was performed
to indicate that gout was or wasn’t the major contributor
to the genetic associations. An analysis of variables was
conducted to study the differences between genotypes
and clinical characteristics in all participants. False Dis-
covery Rate (FDR) correction was applied at the same
time due to multiple comparisons. After correction, a p-
value less than 0.05 was considered statistically signifi-
cant. All these association analyses were performed
using the online software SHEsis (http://shesisplus.bio-x.
cn/) [37], a powerful and user-friendly software platform
for genetic association analysis.
SNP-SNP interactions were conducted using a logistic
regression analysis with the second SNP as a covariate
also by SHEsis (http://shesisplus.bio-x.cn/) [37]. Power
was calculated using obtained unadjusted OR and prob-
ability of exposure in controls with preestablished α
Table 2 Summary of eight SNPs used in analysis
SNP Positiona Gene name and function Minor alleleb Populations and reference MAFc CEU CHB
rs12129861 1q21.1 PDZK1, 5’Intergenic A European (17, 19, 20) 0.460 0.170
rs780094 2p23.3 GCKR, Intron16 A European (17, 19, 20) 0.394 0.566
rs734553 4p10.1 SLC2A9, Intron7 C European (17, 19, 20) 0.261 0.004
rs742132 6p22.2 LRRC16A, Intron34 C European (17, 20) 0.301 0.244
Japanese (21)
rs1183201 6p22.2 SLC17A1, Intron 3 A European (17,20) — —
rs12356193 10q21.2 SLC16A9, Intron 5 G European (17, 19, 20) 0.186 0.141
rs17300741 11q13.1 SLC22A11, Intron4 G European (17, 19, 20) 0.531 0.073
rs505802 11q13.1 SLC22A12, 5’Intergenic A European (17, 19, 20) 0.726 0.256
aon human genome build 18
bin NCBI
ccollected from HapMap Data Phase III/Rel#3. CEU: Utah residents with Northern and Western European ancestry from the CEPH collection, CHB: Han Chinese in
Beijing, China
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Power and Sample Size Calculation Software [38].Results
Phenotype details and biochemical indicators
T test results for phenotypic characteristics between the
two independent cohorts are listed in Table 1. The age
of the two groups was significantly different (51.95 ±
13.68 vs 47.56 ± 12.70 years, p < 0.001). Body mass index
(BMI), diastolic blood pressure and blood glucose, tri-
glycerides, creatinine and uric acid levels of gout pa-
tients were significantly higher than those of controls (all
p < 0.001). Cholesterol levels of gout patients were lower
than those of controls (p = 0.025). Systolic blood pressure
and urea nitrogen level of the two groups were not statisti-
cally different (p = 0.098 and p = 0.715, respectively).SNP association with gout risk
All subjects were genotyped for the eight SNPs and all
SNPs obtained 97.9 % call rates in genotyping (data not
shown in the tables). Up to 18 internal positive and
negative duplicates were examined to control the geno-
typing quality and genotyping results were consistent.
All SNPs achieved genetic equilibrium in both case
and control cohorts (HWE corrected p > 0.05; shown in
Table 3).
Genotype and allele frequency distributions in case–
control cohorts were shown in Table 3. Three SNPs,
rs780094 in GCKR, rs1183201 in 17A1 and rs505802
in SLC22A12 were significantly associated with gout in
our samples. The p values after FDR correction for
rs780094, rs1183201 and rs505802 were 1.78E−4, 1.39E−7
and 0.007, respectively. Each effect allele (the one that
the reported OR correlates with) of these three SNPs
had a same protective effect on gout with the ORs re-
ported as 0.723, 0.572 and 0.747, respectively. However,the remaining SNPs in PDZK1, SLC2A9, LRRC16A,
SLC16A9 and SLC22A11 were not replicated in this
study. Notably, the logistic regression which consid-
ered each of the potential confounding covariates at a
time did not change the genetic associations substan-
tially except for uric acid concentrations, indicating
that gout was the major contributor to the associa-
tions independent of such clinical and biochemical
characteristics (shown in Table 4). The power values
for these SNPs ranged from 7.1 % to 99.8 %. Unfortu-
nately, SNP-SNP interactions for these three signifi-
cant SNPs were not detected (rs780094 vs rs1183201,
p = 0.402; rs780094 vs rs505802, p = 0.434; rs1183201
vs rs505802, p = 0.143).Association of eight SNPs with phenotype details and
biochemical indicators
Both SUA levels and primary gout are complicated
traits and diseases, being closely correlated with sev-
eral other metabolic factors [39]. We checked all par-
ticipants’ questionnaires and confirmed that all cases
were first diagnosed with gout on our gout clinic with-
out receiving any relevant medication. Therefore, we
decided to conduct this genotype–phenotype analysis
in all participants to assess the association of these
SNPs with collected clinical characteristics. We found
significant association of uric acid concentrations with
three gout-related SNPs (rs780094 in GCKR, corrected
p = 3.94E−5; rs1183201 in SLC17A1, corrected p =
0.005; rs505802 in SLC22A12, corrected p = 0.003) and
of triglycerides with rs780094 (located in GCKR, cor-
rected p = 2.96E−4). The remaining SNPs showed no
significant associations with all collected clinical data
(shown in Table 5). The results provide further evi-
dence indicating that gout is the major contributor to
the associations.
Table 3 Association analysis of 8 SUA-related SNPs with gout in Chinese Han males
SNP HWEa Effect Frequency Allele Allelic OR FDR Power
alleleb (case, ctrl) p-value % 95 CI
rs12129861 0.999 A 0.163 0.327 0.907 1 11.4 %
0.393 0.177 [0.747 ~ 1.101]
rs780094 0.999 G 0.394 1.64E−5 0.723 1.78E−4 87.6 %
0.997 0.473 [0.624 ~ 0.838]
rs734553 0.999 C 0.008 0.028 0.456 0.152 68.7 %
0.997 0.018 [0.223 ~ 0.935]
rs742132 0.999 C 0.227 0.538 1.056 1 7.1 %
0.989 0.218 [0.887 ~ 1.257]
rs1183201 0.999 T 0.153 6.39E−9 0.572 1.39E−7 99.8 %
0.067 0.239 [0.473 ~ 0.692]
rs12356193 0.999 G 0.002 0.659 1.43 1 7.2 %
0.997 0.002 [0.288 ~ 7.1]
rs17300741 0.999 G 0.063 0.133 1.27 0.581 19.2 %
0.997 0.050 [0.928 ~ 1.736]
rs505802 0.999 A 0.208 9.88E−4 0.747 0.007 72.2 %
0.997 0.260 [0.628 ~ 0.889]
Results with p value less than 0.05 are shown in boldface
acalculated by FDR
bthe allele that the reported OR correlates with
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This study was performed to assess the association of
eight SUA correlated SNPs first identified in Europeans
with phenotype gout in Han Chinese males. Three
SNPs, rs780094 in GCKR, rs1183201 in SLC17A1 and
rs505802 in SLC22A12 were confirmed to be signifi-
cantly associated with gout and SUA concentrations.
Notably, the logistic regression which considered each
of the potential confounding covariates at a time did
not change the genetic associations substantially except
for SUA concentrations, indicating that gout was the
major contributor to the associations independent of
such clinical and biochemical characteristics. While
the remaining SNPs were not replicated. We also found
a significant association of triglycerides with rs780094
in GCKR.Table 4 Sequential logistic regression analyses that considered each
SNP age BMI SBP DBP Gl
rs12129861 0.788 1 1 0.891 1
rs780094 4.46E−4 5.47E−5 2.36E−4 2.03E−4 2.9
rs734553 0.094 0.183 0.182 0.2 0.1
rs742132 1 1 1 1 1
rs1183201 9.52E−9 2.05E−8 4.69E−8 9.80E−8 2.8
rs12356193 1 1 1 1 1
rs17300741 0.712 0.831 0.575 0.426 0.5
rs505802 0.004 0.01 0.005 0.007 0.0
All p values above were estimated by FDR at the same timeSNP rs780094 in the GCKR gene was found to have a
strong association with gout in our samples, of which
both p value and effect direction were consistent with
our previous study by Wang J et al. [23]. The data sets
of the two studies were not overlapped, demonstrating
its true effect on gout risk in Chinese Han males. How-
ever, this association was not replicated in Germany
[20], whereas validated in Japan [22] and New Zealand
[24]. The direction of the association was consistent
among these populations; however, we note that the
minor allele frequency (MAF) between the Asians and
Europeans was different: the minor allele for Chinese
and Japanese was ‘G’ with MAF of 0.473 and 0.444 re-
spectively, consistent with HapMap data (MAF = 0.366
and 0.401, respectively); while the minor allele for
Germany and New Zealand population was ‘A’ withof the potential confounding covariates at a time
u Tri Cho UN Cre UA
1 1 1 0.851 1
7E−4 0.025 1.78E−4 1.66E−4 1.36E−4 1
9 0.116 0.178 0.167 0.167 0.19
1 1 1 1 1
5E−8 1.48E−6 5.49E−8 5.17E−8 3.5E−8 0.005
1 1 1 1 1
2 0.238 0.648 0.544 0.766 0.19
03 0.013 0.006 0.006 0.005 0.779
Table 5 Associations between clinical data and genotypes of the eight SNPs
rs12129861 rs780094 rs734553 rs742132 rs1183201 rs12356193 rs17300741 rs505802
Age 0.615 0.615 0.963 1 0.963 0.615 1 1
BMI 1 1 1 1 1 1 1 1
SBP 1 0.301 1 0.334 1 1 1 1
DBP 1 1 1 1 1 1 1 1
Glu 1 1 1 1 1 1 1 1
Tri 1 2.96E−4 1 1 0.131 1 1 1
Cho 1 1 1 1 1 1 1 1
UN 0.8 1 1 0.8 1 1 0.315 0.8
Cre 1 1 1 1 1 1 1 1
UA 0.117 3.94E−5 1 1 0.005 1 1 0.003
All p values were estimated by FDR at the same time. Results with p value less than 0.05 are shown in boldface
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HapMap-CEU data (MAF = 0.394). Besides, we extracted
the genotype data across the gene for Han Chinese and
Europeans from the HapMap database and explored the
difference of genomic structure and LD between Chinese
and Europeans using HaploView software (version 4.2).
LD plot for the two populations is shown in Fig. 1. SNP
rs780093 in the GCKR gene was in very high LD with
rs780094 (r2 = 1.0) in both Chinese and Europeans. How-
ever, the linkage degree around rs780094 in Europeans was
obviously higher than that of Chinese. Therefore, the differ-
ences of genetic background in different populations indeed
exist and more validation tests with larger sample size are
needed across various populations. The GCKR gene en-
codes the glucokinase regulatory protein, which regulates
glucokinase (GCK) activity [40]. GCK, also known as hexo-
kinase 4, catalyzes the phosphorylation of glucose into
glucose-6-phosphate and thus modulates hepatic glucose
homeostasis [41]. ‘A’ allele of rs780094 has been observed
to be associated with lower fasting glucose level and higher
triglycerides in different ethnic groups [42–45]. In thisFig. 1 LD plot for Chinese and Europeans, respectivelystudy, ‘A’ allele was also observed to be associated with
higher triglycerides in Han Chinese individuals, but not
with glucose level or other biochemical indicators. A study
from Hong Kong reported that the interaction between
rs1799884 and rs780094 weakened the correlation of
rs780094 with fasting glucose level in Chinese population
[46]. Rs780094 AA genotype frequency in Chinese Han
population is much higher compared with European
populations (27 % and 14 %, respectively) and thus the
interaction between SNPs in Han Chinese is stronger.
Therefore, it’s much harder to observe the association of
rs780094 with fasting glucose in Chinese population, which
urgently needs to be confirmed in larger samples. Although
the association of rs780094 with gout has been indeed
corroborated in Han Chinese, Japanese and New Zealand
populations, the pathway of this locus on gout development
is still completely unknown. In the future, relevant func-
tional experiments are needed to delineate the exact in-
volvement of this gene in gout.
The next significant locus in this study was rs505802
within the SLC22A12 gene. The SLC22A12 locus encodes
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porter (OAT) involved in the non-voltage-dependent ex-
change of uric acid for organic anions [47]. Many studies
have shown significant associations between SNPs in
SLC22A12 and SUA levels or/and gout. For example, two
independent GWAS of SUA level for Croatia population
and African Americans identified rs505802 and rs12800450
to be significant loci respectively [48, 49]. Another GWAS
by Kamatani et al. and a meta-analysis by Okada et al. both
from Japan discovered rs506338 and rs504195 to be associ-
ated with SUA concentrations respectively[13, 14]. Follow-
up replications across multiple ethnics including New
Zealand populations, Japanese and Han Chinese succes-
sively identified additional SNPs in SLC22A12 gene associ-
ated with gout or hyperuricemia [22, 24, 27]. SNP
rs3825018 (in complete LD with rs505802) also achieved
nominal significance in New Zealand case–control sample
sets (p = 0.002) [50]. However, this association was not
confirmed in German population [20]. And we noted that
the MAF of this SNP in Chinese and Germans was differ-
ent: the minor allele for Chinese was ‘A’ with MAF of
0.260, consistent with HapMap-CHB (MAF = 0.244);
while the minor allele for Germans was ‘G’ with MAF of
0.315, consistent with HapMap-CEU (MAF = 0.274) [20].
The different genotype distributions across multiple eth-
nics may at least partly account for the discordant results.
The strongest association in the present study was
rs1183201 within SLC17A1 gene. SLC17A1 encodes the
solute carrier family 17 member 1, also known as so-
dium phosphate transport protein 1 (NPT1), which has
been identified as a urate transport protein [51]. GWAS
or meta-analysis of SUA level among different populations
has shown inconsistent results for SLC17A1 loci:
rs1183201 was confirmed to be associated with SUA level
among Japanese [13] and Europeans [8, 17] rather than
Chinese [11] and Croatia population [48]. Two independent
replication studies provided strong evidence for a role
of rs1183201 in gout in New Zealand Caucasians [24, 25]
and rs1165196 (in high LD with rs1183201, r2 = 0.915
in HapMap-JPT) was also replicated in Japanese population
[22]. However, it was not associated with gout in a recent
study by Wan W et al. [35]. The inconsistent results may
indicate the complex pathogenesis of gout, which needs
more studies to better elaborate the etiology for such
different presentations.
However, we did not detect the association with gout
for the remaining SNPs. It’s noteworthy that these nega-
tive SNPs could only explain less than 0.20℅ of variabil-
ity on SUA level except for rs734553 in SLC2A9 gene
with explained variability of 3.53℅ [20]. From the clinical
observation, less than ten percent of hyperuricemia pa-
tients we examined experienced gouty arthritis in their
lifetime. Uric acid metabolism is a risk factor, but cannot
fully explain the development of gouty arthritis [1]. Wespeculate that there may be a different pathogenesis
between the two conditions, which may explain our
negative results at these SUA sensitive loci. In the power
analysis, we note that the power of rs12129861, rs742132
and rs12356193 was as low as 11.4 %, 7.1 % and 7.2 % re-
spectively, almost insufficient to detect their association
with gout in such a sample size. Considering the low power
values of these SNPs, the negative results of these loci
lacked enough evidence. The results may be false negative
due to the small sample size, which urgently needs to be
confirmed in the further study. In addition, rs734553 was
significantly associated with gout in Germans [20], however,
the association was not replicated in the present study. This
might result from the very low MAF of 0.018 in Chinese
males compared to that of 0.253 in Germans.
Almost all kinds of biological traits and complex dis-
eases are results of multiple gene interaction and thus
understanding gene interactions on disease is indeed ne-
cessary. However, in the present study, SNP-SNP inter-
actions were not detected for the three significant SNPs.
In contrast, there was a weak epistasis between rs734553
and rs742132 in the study by Stark et al., suggesting that
there may be differences of gene interactions on gout
risk among different populations [20].
Our study had several limitations. We did not evaluate
lifestyle factors such as high-purine diet, smoking and
drinking, which also had a significant impact on com-
plex diseases including gout. There were two rare vari-
ants in our samples, rs734553 and rs12356193, a finding
consistent with the HAPMAP database. Traditional as-
sociation method lacks sufficient power to detect such
rare variants and second-generation sequencing is more
valuable. Several genes including SLC2A9 possess obvi-
ous gender differences on gout risk [9] and understand-
ing the genetic mechanisms of female gout is equally
important. But due to less than 5 % of our outpatients
were female, not sufficient to conduct a statistical ana-
lysis, this study focused on Han Chinese males only.
Conclusions
Three SUA correlated SNPs, rs780094 in GCKR, rs734553
in SLC2A9 and rs505802 in SLC22A12 were confirmed to
be associated with gout arthritis in Han Chinese males.
Considering genetic differences among populations and
complicated pathogenesis of gout arthritis, more validating
tests in independent populations and relevant functional
experiments are suggested in future.
Availability of Supporting Data
The supporting data underlying the results was included
as additional files.
Abbreviations
SUA: Serum uric acid; SNPs: Single nucleotide polymorphisms;
GWAS: Genome-wide association studies; LD: Linkage disequilibrium;
Zhou et al. BMC Medical Genetics  (2015) 16:66 Page 8 of 9HWE: Hardy-Weinberg equilibrium; ORs: Odds ratios; CI: Confidence intervals;
FDR: False Discovery Rate; BMI: Body mass index; GCK: Glucokinase;
MAF: Minor Allele Frequency; URAT1: Urate anion exchanger 1; OAT: Organic
anion transporter; NPT1: Sodium phosphate transport protein 1.
Competing interests
The authors declare that they have no competing interests.
Authors contributions
CGL and YYS are common corresponding authors and supervised the entire
project. ZWZ, LLC and LH, first co-authors, involved in the whole experiment
and composed the article. CW and XMW collected samples. ZJS, JWS, ZQL,
JHC, ZJW assisted in the completion of data processing. All authors have
read and approved the final version of the manuscript.
Funding
This work was supported by the National Science Fundation of China
(31371272, 31471195 and 81100621) and Shandong province science and
technology development plan item (2014GSF118013).
Acknowledgements
This work was supported by Shandong Provincial Key Laboratory of
Metabolic Disease, the Affiliated Hospital of Qingdao University, Qingdao
266003, China and Bio-X Institutes of Shanghai Jiao Tong University,
Shanghai 200030, China. We also thank all subjects’ voluntary participation.
Author details
1Shandong Gout Clinical Medical Center, The Affiliated Hospital of Qingdao
University, 16 Jiangsu Road, Qingdao 266003, China. 2Shandong Provincial
Key Laboratory of Metabolic Disease, The Affiliated Hospital of Qingdao
University, 16 Jiangsu Road, Qingdao 266003, China. 3Bio-X Institutes, Key
Laboratory for the Genetics of Developmental and Neuropsychiatric
Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai
200030, China.
Received: 15 January 2015 Accepted: 30 July 2015
References
1. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12:223.
2. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al.
Gout in the UK and Germany: prevalence, comorbidities and management
in general practice 2000–2005. Ann Rheum Dis. 2008;67:960–6.
3. Chuang SY, Lee SC, Hsieh YT, Pan WH. Trends in hyperuricemia and gout
prevalence: Nutrition and Health Survey in Taiwan from 1993–1996 to
2005–2008. Asia Pac J Clin Nutr. 2011;20:301–8.
4. Miao Z, Li C, Chen Y, Zhao S, Wang Y, Wang Z, et al. Dietary and lifestyle
changes associated with high prevalence of hyperuricemia and gout in the
Shandong coastal cities of Eastern China. J Rheumatol. 2008;35:1859–64.
5. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US
general population: the National Health and Nutrition Examination Survey
2007–2008. Arthritis Rheum. 2011;63:3136–41.
6. Brook RA, Kleinman NL, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE,
et al. The economic burden of gout on an employed population. Curr Med
Res Opin. 2006;22:1381–9.
7. Wilk JB, Djousse L, Borecki I, Atwood LD, Hunt SC, Rich SS, et al. Segregation
analysis of serum uric acid in the NHLBI Family Heart Study. Hum Genet.
2000;106:355–9.
8. Dehghan A, Kottgen A, Yang Q, Hwang SJ, Kao WL, Rivadeneira F, et al.
Association of three genetic loci with uric acid concentration and risk of
gout: a genome-wide association study. Lancet. 2008;372:1953–61.
9. Doring A, Gieger C, Mehta D, Gohlke H, Prokisch H, Coassin S, et al. SLC2A9
influences uric acid concentrations with pronounced sex-specific effects.
Nat Genet. 2008;40:430–6.
10. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, et al. SLC2A9 is a
newly identified urate transporter influencing serum urate concentration,
urate excretion and gout. Nat Genet. 2008;40:437–42.
11. Yang B, Mo Z, Wu C, Yang H, Yang X, He Y, et al. A genome-wide
association study identifies common variants influencing serum uric acid
concentrations in a Chinese population. BMC Med Genet. 2014;7:10.
12. Yang Q, Kottgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, et al.
Multiple genetic loci influence serum urate levels and their relationship withgout and cardiovascular disease risk factors. Circ Cardiovasc Genet.
2010;3:523–30.
13. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y, et al.
Genome-wide association study of hematological and biochemical traits in
a Japanese population. Nat Genet. 2010;42:210–5.
14. Okada Y, Sim X, Go MJ, Wu JY, Gu D, Takeuchi F, et al. Meta-analysis
identifies multiple loci associated with kidney function-related traits in east
Asian populations. Nat Genet. 2012;44:904–9.
15. Sull JW, Yang SJ, Kim S, Jee SH. The ABCG2 Polymorphism rs2725220 Is
Associated with Hyperuricemia in the Korean Population. Genome Inform.
2014;12:231–5.
16. Voruganti VS, Kent Jr JW, Debnath S, Cole SA, Haack K, Goring HH, et al.
Genome-wide association analysis confirms and extends the association of
SLC2A9 with serum uric acid levels to Mexican Americans. Front Genet.
2013;4:279.
17. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, et al. Meta-analysis
of 28,141 individuals identifies common variants within five new loci that
influence uric acid concentrations. PLoS Genet. 2009;5:e1000504.
18. Kottgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al.
Genome-wide association analyses identify 18 new loci associated with
serum urate concentrations. Nat Genet. 2013;45:145–54.
19. van der Harst P, Bakker SJ, de Boer RA, Wolffenbuttel BH, Johnson T,
Caulfield MJ, et al. Replication of the five novel loci for uric acid
concentrations and potential mediating mechanisms. Hum Mol Genet.
2010;19:387–95.
20. Stark K, Reinhard W, Grassl M, Erdmann J, Schunkert H, Illig T, et al. Common
polymorphisms influencing serum uric acid levels contribute to susceptibility to
gout, but not to coronary artery disease. PLoS One. 2009;4:e7729.
21. Sakiyama M, Matsuo H, Shimizu S, Chiba T, Nakayama A, Takada Y, et al.
Common variant of leucine-rich repeat-containing 16A (LRRC16A) gene is
associated with gout susceptibility. Hum Cell. 2014;27:1–4.
22. Urano W, Taniguchi A, Inoue E, Sekita C, Ichikawa N, Koseki Y, et al.
Effect of genetic polymorphisms on development of gout. J Rheumatol.
2013;40:1374–8.
23. Wang J, Liu S, Wang B, Miao Z, Han L, Chu N, et al. Association between
gout and polymorphisms in GCKR in male Han Chinese. Hum Genet.
2012;131:1261–5.
24. Phipps-Green AJ, Merriman ME, Topless R, Altaf S, Montgomery GW,
Franklin C et al.: Twenty-eight loci that influence serum urate levels:
analysis of association with gout. Annals of the rheumatic diseases
2014 Sep 3.
25. Hollis-Moffatt JE, Phipps-Green AJ, Chapman B, Jones GT, van Rij A, Gow PJ,
et al. The renal urate transporter SLC17A1 locus: confirmation of association
with gout. Arthritis Res Ther. 2012;14:R92.
26. Guan M, Zhou D, Ma W, Chen Y, Zhang J, Zou H. Association of an intronic
SNP of SLC2A9 gene with serum uric acid levels in the Chinese male
Han population by high-resolution melting method. Clin Rheumatol.
2011;30:29–35.
27. Tu HP, Chen CJ, Tovosia S, Ko AM, Lee CH, Ou TT, et al. Associations of a
non-synonymous variant in SLC2A9 with gouty arthritis and uric acid
levels in Han Chinese subjects and Solomon Islanders. Ann Rheum Dis.
2010;69:887–90.
28. Dong Z, Guo S, Yang Y, Wu J, Guan M, Zou H, Jin L, Wang J. Association
between ABCG2 Q141K polymorphism and gout risk affected by ethnicity
and gender: a systematic review and meta-analysis. International journal of
rheumatic diseases. 2015 May;18(4):382–91.
29. Li FG, Chu Y, Meng DM, Tong YW. [Association of ABCG2 gene C421A
polymorphism and susceptibility of primary gout in Han Chinese males].
Zhonghua yi xue yi chuan xue za zhi. 2011;28:683–5.
30. Wang B, Miao Z, Liu S, Wang J, Zhou S, Han L, et al. Genetic analysis of
ABCG2 gene C421A polymorphism with gout disease in Chinese Han male
population. Hum Gen. 2010;127:245–6.
31. Zhou D, Liu Y, Zhang X, Gu X, Wang H, Luo X, et al. Functional
polymorphisms of the ABCG2 gene are associated with gout disease in the
Chinese Han male population. Int J Mol Sci. 2014;15:9149–59.
32. Li C, Han L, Levin AM, Song H, Yan S, Wang Y, et al. Multiple single nucleotide
polymorphisms in the human urate transporter 1 (hURAT1) gene are associated
with hyperuricaemia in Han Chinese. J Med Genet. 2010;47:204–10.
33. Li C, Yu Q, Han L, Wang C, Chu N, Liu S. The hURAT1 rs559946
polymorphism and the incidence of gout in Han Chinese men. Scand J
Rheumatol. 2014;43:35–42.
Zhou et al. BMC Medical Genetics  (2015) 16:66 Page 9 of 934. Tu HP, Chen CJ, Lee CH, Tovosia S, Ko AM, Wang SJ, et al. The SLC22A12
gene is associated with gout in Han Chinese and Solomon Islanders. Ann
Rheum Dis. 2010;69:1252–4.
35. Wan W, Xu X, Zhao DB, Pang YF, Wang YX. Polymorphisms of uric
transporter proteins in the pathogenesis of gout in a Chinese Han
population. Genet Mol Res. 2015;14:2546–50.
36. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary
criteria for the classification of the acute arthritis of primary gout. Arthritis
Rheum. 1977;20:895–900.
37. Li Z, Zhang Z, He Z, Tang W, Li T, Zeng Z, et al. A partition-ligation-combination-
subdivision EM algorithm for haplotype inference with multiallelic markers:
update of the SHEsis (http://analysis.bio-x.cn). Cell Res. 2009;19:519–23.
38. Dupont WD, Plummer Jr WD. Power and sample size calculations for
studies involving linear regression. Control Clin Trials. 1998;19:589–601.
39. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J
Med. 2008;359:1811–21.
40. Orho-Melander M, Melander O, Guiducci C, Perez-Martinez P, Corella D, Roos
C, et al. Common missense variant in the glucokinase regulatory protein gene is
associated with increased plasma triglyceride and C-reactive protein but lower
fasting glucose concentrations. Diabetes. 2008;57:3112–21.
41. Tang L, Ye H, Hong Q, Wang L, Wang Q, Wang H, et al. Elevated CpG island
methylation of GCK gene predicts the risk of type 2 diabetes in Chinese
males. Gene. 2014;547:329–33.
42. Diabetes Genetics Initiative of Broad Institute of H, Novartis Institutes of
BioMedical R, Mit LU, Saxena R, Voight BF, Lyssenko V, et al. Genome-wide
association analysis identifies loci for type 2 diabetes and triglyceride levels.
Science. 2007;316:1331–6.
43. Qi Q, Wu Y, Li H, Loos RJ, Hu FB, Sun L, et al. Association of GCKR rs780094,
alone or in combination with GCK rs1799884, with type 2 diabetes and
related traits in a Han Chinese population. Diabetologia. 2009;52:834–43.
44. Sparso T, Andersen G, Nielsen T, Burgdorf KS, Gjesing AP, Nielsen AL, et al.
The GCKR rs780094 polymorphism is associated with elevated fasting serum
triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced
risk of type 2 diabetes. Diabetologia. 2008;51:70–5.
45. Vaxillaire M, Cavalcanti-Proenca C, Dechaume A, Tichet J, Marre M, Balkau B,
et al. The common P446L polymorphism in GCKR inversely modulates
fasting glucose and triglyceride levels and reduces type 2 diabetes risk in
the DESIR prospective general French population. Diabetes. 2008;57:2253–7.
46. Tam CH, Ma RC, So WY, Wang Y, Lam VK, Germer S, et al. Interaction effect
of genetic polymorphisms in glucokinase (GCK) and glucokinase regulatory
protein (GCKR) on metabolic traits in healthy Chinese adults and
adolescents. Diabetes. 2009;58:765–9.
47. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al.
Molecular identification of a renal urate anion exchanger that regulates
blood urate levels. Nature. 2002;417:447–52.
48. Karns R, Zhang G, Sun G, Rao Indugula S, Cheng H, Havas-Augustin D, et al.
Genome-wide association of serum uric acid concentration: replication of
sequence variants in an island population of the Adriatic coast of Croatia.
Ann Hum Genet. 2012;76:121–7.
49. Tin A, Woodward OM, Kao WH, Liu CT, Lu X, Nalls MA, et al. Genome-wide
association study for serum urate concentrations and gout among African
Americans identifies genomic risk loci and a novel URAT1 loss-of-function
allele. Hum Mol Genet. 2011;20:4056–68.
50. Flynn TJ, Phipps-Green A, Hollis-Moffatt JE, Merriman ME, Topless R,
Montgomery G, et al. Association analysis of the SLC22A11 (organic anion
transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus
with gout in New Zealand case–control sample sets reveals multiple
ancestral-specific effects. Arthritis Res Ther. 2013;15:R220.
51. Iharada M, Miyaji T, Fujimoto T, Hiasa M, Anzai N, Omote H, et al. Type 1
sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl
(−)-dependent urate exporter. J Biol Chem. 2010;285:26107–13.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
